Table 3.

Proportional hazards of recurrence-free survival (only factors with a p-value < 0.05 are shown).

	HR	Lower 95% CI	Upper 95% CI	p-value	HR	Lower 95% CI	Upper 95% CI	p-value
LT before 16 December 2006 (pre-MELD era)	0.559	0.319	0.980	0.042
Female gender	1.903	1.062	3.412	0.031
Outside Milan criteria (explant)	3.451	1.982	6.009	<0.001
Outside Milan but inside UCSF criteria (explant)	2.891	1.669	5.007	<0.001
Outside Milan but inside up-to-seven criteria (explant)	4.148	2.387	7.208	<0.001
T stage (explant; T0 = reference)				<0.001				0.047
T1	0.776	0.282	2.135	0.623	0.711	0.269	1.879	0.491
T2	1.554	0.624	3.871	0.344	1.018	0.402	2.573	0.970
T3	5.164	1.981	13.463	0.001	2.541	0.914	7.061	0.074
T4	82.839	7.499	915.062	<0.001	0.000	0.000		0.994
Grading (G1 = reference)				0.006
G2	1.139	0.497	2.609	0.759
G3	2.910	1.185	7.147	0.020
Gx	0.270	0.033	2.195	0.221
Number of tumour nodules (0 = reference)				<0.001
1	0.957	0.337	2.716	0.934
2	1.161	0.311	4.324	0.824
3	1.954	0.565	6.756	0.290
>3	4.807	1.838	12.569	0.001
Nodule size > 5 cm	1.998	1.025	3.897	0.042
Microvascular invasion	3.249	1.796	5.878	<0.001
NASH	4.575	1.411	14.834	0.011
AFP (ng/mL) before LT	1.001	1.001	1.002	<0.001	1.001	1.000	1.002	0.007

Multivariate analysis was performed on variables with a p-value < 0.01 in the univariate analysis.

AFP: alpha-fetoprotein; CI: confidence interval; HR: hazard ratio; LT: liver transplantation; MELD: model for end-stage liver disease; NASH: nonalcoholic steatohepatitis; UCSF: [University of California San Francisco]; p-values<0.05 are considered to be statistically significant and are highlighted in bold.